Proactively manage your pharmacy inventory
Find generic entry opportunities
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||Described are antihypertensive agents selected from the class consisting of 2[4(tetrahydro-2-furoyl)-piperazino]-4-amino-6,7-dimethoxyquinazoline and 2-[4(tetrahydropyran-2-carbonyl)-piperazinyl]-4-amino-6,7-dimethoxyquinazo line, and pharmaceutically acceptable acid addition salts thereof. The compounds are highly water soluble and can be administered in time release form as well as parenterally, including intravenously.|
|Inventor(s):||Winn; Martin (Deerfield, IL), Kyncl; Jaroslav (Lake Bluff, IL), Dunnigan; Daniel Ambrose (Winthrop Harbor, IL), Jones; Peter Hadley (Lake Forest, IL)|
|Assignee:||Abbott Laboratories (North Chicago, IL)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Australia||498925||<disabled in preview>|
|Australia||1655776||<disabled in preview>|
|Canada||1057754||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.